• Johnson & Johnson's (NYSE:JNJ) earnings per share are expected to decrease to $2.02 from $2.29.
• Revenue is projected to rise to $22.45 billion, indicating a positive sales performance trend.
• The FDA's approval of Spravato nasal spray for expanded use could boost future sales.

Johnson & Johnson (NYSE:JNJ) is a global healthcare company known for its pharmaceuticals, medical devices, and consumer health products. On January 22, 2025, Johnson Rice updated its rating for JNJ to Neutral, maintaining a hold action. At the time, the stock price was $148.15. This update comes as the company prepares to release its fourth-quarter earnings results.

Analysts expect Johnson & Johnson to report earnings of $2.02 per share for the fourth quarter, a decrease from $2.29 per share in the same period last year. Despite this decline in earnings per share, revenue is projected to rise to $22.45 billion, up from $21.39 billion a year earlier. This indicates a positive trend in the company's overall sales performance.

A significant development for Johnson & Johnson is the FDA's approval of its Spravato nasal spray for expanded use. The spray is now approved as a standalone treatment for adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval enhances Johnson & Johnson's psychiatric drug portfolio, potentially boosting future sales.

Ahead of the earnings announcement, JNJ shares increased by 0.8%, closing at $148.15. The stock has experienced a decline of 8.88% over the past year but has seen a 2.79% increase year-to-date. This recent uptick in stock price reflects investor optimism surrounding the company's upcoming earnings report and recent regulatory success.

Johnson & Johnson's market capitalization stands at approximately $356.69 billion, with a trading volume of 8,262,191 shares. The stock has fluctuated between a low of $147.05 and a high of $148.85 today. Over the past year, JNJ has reached a high of $168.85 and a low of $140.68, indicating some volatility in its stock performance.